PLX 200
/ Polaryx
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 30, 2025
Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3
(clinicaltrials.gov)
- P3 | N=39 | Not yet recruiting | Sponsor: Polaryx Therapeutics, Inc. | Trial completion date: Dec 2025 ➔ Mar 2026 | Trial primary completion date: Dec 2025 ➔ Mar 2026
Trial completion date • Trial primary completion date • CNS Disorders
April 01, 2022
Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3
(clinicaltrials.gov)
- P3 | N=39 | Not yet recruiting | Sponsor: Polaryx Therapeutics, Inc. | Trial completion date: Aug 2024 ➔ Dec 2025 | Trial primary completion date: Feb 2023 ➔ Dec 2025
Trial completion date • Trial primary completion date • CNS Disorders
July 19, 2021
Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3
(clinicaltrials.gov)
- P3; N=39; Not yet recruiting; Sponsor: Polaryx Therapeutics, Inc.; Phase classification: P2 ➔ P3; N=24 ➔ 39; Initiation date: Feb 2021 ➔ Sep 2021
Clinical • Enrollment change • Phase classification • Trial initiation date • CNS Disorders
November 19, 2020
Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3
(clinicaltrials.gov)
- P2; N=24; Not yet recruiting; Sponsor: Polaryx Therapeutics, Inc.
Clinical • New P2 trial • CNS Disorders
1 to 4
Of
4
Go to page
1